Ipatasertib联合阿比特龙和泼尼松龙治疗转移性去势抵抗性前列腺癌(IPATential150):一项多中心、随机、双盲、3期试验
IPATential150是一项多中心、随机、双盲3期试验,纳入1101例既往未治疗的mCRPC患者,随机接受Ipatasertib(400 mg每日一次口服)联合阿比特龙(1000 mg每日一次口服)和泼尼松龙(5 mg每日两次口服)或安慰剂联合阿比特龙和泼尼松龙。联合组3级及以上不良事件发生率为70% vs 39%,导致停药的不良事件为21% vs 5%。
要点
- 联合组3级及以上不良事件发生率70%(386/551),安慰剂组39%(213/546);导致停药的不良事件分别为21%(116例)和5%(28例)。
- 治疗相关不良事件死亡:联合组2例(<1%,高血糖和化学性肺炎),安慰剂组2例(<1%,急性心肌梗死和下呼吸道感染)。
- 适用人群为既往未治疗的无症状或轻度症状mCRPC、ECOG体能状态0或1、有疾病进展的患者。
适用人群与场景
- 年龄18岁及以上、既往未治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,无症状或轻度症状,有疾病进展,ECOG体能状态0或1。
- 分层因素包括:既往针对激素敏感性前列腺癌的紫杉类治疗、进展类型、内脏转移 presence、肿瘤PTEN缺失状态(免疫组化)。
诊断标准与关键阈值
- PTEN缺失状态通过免疫组化评估;PTEN缺失患者共521例(47%)。
- 主要终点为研究者评估的影像学无进展生存期,在PTEN缺失(免疫组化)人群和意向治疗人群中共同主要分析。
处置流程与药物剂量
- 第一步:筛选符合条件的既往未治疗mCRPC患者,评估PTEN缺失状态(免疫组化)。
- 第二步:随机1:1分配至Ipatasertib 400 mg每日一次口服 + 阿比特龙1000 mg每日一次口服 + 泼尼松龙5 mg每日两次口服,或安慰剂 + 阿比特龙1000 mg每日一次口服 + 泼尼松龙5 mg每日两次口服。
- 第三步:治疗持续至疾病进展、不可耐受毒性、退出研究或研究完成。
- 监测不良事件:联合组3级及以上不良事件70%,导致停药21%;需关注高血糖、化学性肺炎、急性心肌梗死、下呼吸道感染等。
红旗征与不能漏的情况
- 联合组治疗相关死亡2例(<1%):高血糖和化学性肺炎;安慰剂组2例(<1%):急性心肌梗死和下呼吸道感染。
- 联合组3级及以上不良事件发生率70%,导致停药的不良事件21%,需密切监测并及时处理毒性。
研究设计与关键结果
- 研究类型:多中心、随机、双盲、3期试验;200个中心,26个国家或地区;纳入1101例患者(筛选1611例,68%入组),安慰剂-阿比特龙组554例,Ipatasertib-阿比特龙组547例。
- 3级及以上不良事件:联合组386/551(70%)vs 安慰剂组213/546(39%);导致停药的不良事件:联合组116例(21%)vs 安慰剂组28例(5%)。
- 治疗相关死亡:联合组2例(<1%,高血糖、化学性肺炎),安慰剂组2例(<1%,急性心肌梗死、下呼吸道感染)。
证据类型、等级与局限
- 证据类型:多中心、随机、双盲、3期试验(RCT)。
- 局限性:意向治疗人群主要终点未达到显著性阈值;联合组不良事件和停药率显著高于安慰剂组;研究正在进行中。
对床旁实践的改变
- 对于PTEN缺失(免疫组化)的既往未治疗mCRPC患者,可考虑Ipatasertib联合阿比特龙和泼尼松龙治疗,但需权衡显著增加的不良事件和停药风险。
- 不适用于意向治疗人群的普遍获益;联合组3级及以上不良事件70%和停药21%需在治疗前充分评估和监测。
指南或共识出处
- IPATential150试验(NCT03072238),发表于Lancet。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib plus abiraterone might have greater benefit than abiraterone alone. We aimed to compare ipatasertib plus abiraterone with placebo plus abiraterone in patients with previously untreated mCRPC with or without tumour PTEN loss.
METHODS: We did a randomised, double-blind, phase 3 trial at 200 sites across 26 countries or regions. Patients aged 18 years or older with previously untreated asymptomatic or mildly symptomatic mCRPC who had progressive disease and Eastern Collaborative Oncology Group performance status of 0 or 1 were randomly assigned (1:1; permuted block method) to receive ipatasertib (400 mg once daily orally) plus abiraterone (1000 mg once daily orally) and prednisolone (5 mg twice a day orally) or placebo plus abiraterone and prednisolone (with the same dosing schedule). Patients received study treatment until disease progression, intolerable toxicity, withdrawal from the study, or study completion. Stratification factors were previous taxane-based therapy for hormone-sensitive prostate cancer, type of progression, presence of visceral metastasis, and tumour PTEN-loss status by immunohistochemistry. Patients, investigators, and the study sponsor were masked to the treatment allocation. The coprimary endpoints were investigator-assessed radiographical progression-free survival in the PTEN-loss-by-immunohistochemistry population and in the intention-to-treat population. This study is ongoing and is registered with ClinicalTrials.gov, NCT03072238.
FINDINGS: Between June 30, 2017, and Jan 17, 2019, 1611 patients were screened for eligibility and 1101 (68%) were enrolled; 554 (50%) were assigned to the placebo-abiraterone group and 547 (50%) to the ipatasertib-abiraterone group. At data cutoff (March 16, 2020), median follow-up duration was 19 months (range 0-33). In the 521 (47%) patients who had tumours with PTEN loss by immunohistochemistry (261 in the placebo-abiraterone group and 260 in the ipatasertib-abiraterone group), median radiographical progression-free survival was 16·5 months (95% CI 13·9-17·0) in the placebo-abiraterone group and 18·5 months (16·3-22·1) in the ipatasertib-abiraterone group (hazard ratio [HR] 0·77 [95% CI 0·61-0·98]; p=0·034; significant at α=0·04). In the intention-to-treat population, median progression-free survival was 16·6 months (95% CI 15·6-19·1) in the placebo-abiraterone group and 19·2 months (16·5-22·3) in the ipatasertib-abiraterone group (HR 0·84 [95% CI 0·71-0·99]; p=0·043; not significant at α=0·01). Grade 3 or higher adverse events occurred in 213 (39%) of 546 patients in the placebo-abiraterone group and in 386 (70%) of 551 patients in the ipatasertib-abiraterone group; adverse events leading to discontinuation of placebo or ipatasertib occurred in 28 (5%) in the placebo-abiraterone group and 116 (21%) in the ipatasertib-abiraterone group. Deaths due to adverse events deemed related to treatment occurred in two patients (<1%; acute myocardial infarction [n=1] and lower respiratory tract infection [n=1]) in the placebo-abiraterone group and in two patients (<1%; hyperglycaemia [n=1] and chemical pneumonitis [n=1]) in the ipastasertb-abiraterone group.
INTERPRETATION: Ipatasertib plus abiraterone significantly improved radiographical progression-free survival compared with placebo plus abiraterone among patients with mCRPC with PTEN-loss tumours, but there was no significant difference between the groups in the intention-to-treat population. Adverse events were consistent with the known safety profiles of each agent. These data suggest that combined AKT and androgen-receptor signalling pathway inhibition with ipatasertib and abiraterone is a potential treatment for men with PTEN-loss mCRPC, a population with a poor prognosis.
FUNDING: F Hoffmann-La Roche and Genentech.
参考来源
- Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021. PMID: 34246347. doi:10.1016/S0140-6736(21)00580-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。